BD launches point-of-care SARS-CoV-2 antigen test

July 7, 2020—Becton Dickinson announced that the FDA granted emergency use authorization to the BD Veritor Plus System for Rapid Detection of SARS-CoV-2 Assay, a rapid, point-of-care, diagnostic test for use with the BD Veritor Plus System.

BD clinical studies performed at more than 20 sites in the United States demonstrated that the test is capable of achieving 84 percent sensitivity and 100 percent specificity. The assay delivers results in 15 minutes.

“This will be a game-changer for frontline health care workers and their patients to be able to access a quick diagnostic test for COVID-19, offering results in real-time at convenient locations like retail pharmacies, urgent care centers, and doctors’ offices,” Dave Hickey, president of integrated diagnostic solutions for BD, said in a press statement.

The BD Veritor System offers customers real-time reporting capabilities through the BD Synapsys informatics solution, which provides users the ability to easily report data for disease monitoring and surveillance purposes.

BD expects to increase capacity to be able to 2 million tests per week by the end of September.